# Use of 3,7,11,15 tetramethyl 2,4,6,10,14 hexadecapentaenoic acid for enhancing the effect of anti tumour agents.

## Abstract
3,7,11,15 tetramethyl 2,4,6,10,14 hexadecapentaenoic acid or a salt thereof can enhance the anti tumor effect of an anti tumor agent.

## Claims
Claims 1. A pharmaceutical use of 3,7,11,15 tetramethyl 2 ,4,6,10,1 4 hexadecapentaenoic acid or a salt thereof for enhancing the antitumor effect. 2. A pharmaceutical use of 3,7,11,15 tetramethyl 2,4,6,10,14 hexadecapentaenoic acid or a salt thereof for preparing a pharmaceutical composition to enhance the anti tumor effect. 3. A pharmaceutical composition which comprises A 3,7,11,15 tetramethyl 2,4,6,1Q,14 hexadecapentaenoic acid or a salt thereof and B an anti tumor agent.

## Description
Pharmaceutical Agent to Enhance the Anti Tumor Effect The invention relates to a pharmaceutical agent to enhance the anti tumor effect. In particular, the agent comprises 3,7,11,15 tetramethyl 2,4,6,10,14 hexadecapentaenoic acid of the formula 1 or a salt thereof.EMI1.1 In the field of chemotherapy of cancer where the development of novel carcinostatic drugs is becoming more and more difficult all the world over, it is a very important problem to try to enhance the effect of known carcinostatic drugs. The inventors of the present invention agave long studied on a carcinostatic synergist and have found that 3,7,ll,15 tetramethyl 2,4,6,1O,14 hexadecapentaenoic acid or its salt I is remarkably effective in enhancing a carcinostatic effect. The present invention has been accomplished based on this finding. The compound I of the present invention has also been found to be effective as an antineoplastic drug or a medicine for dermatopathy accompanied by carnification and applications for patent with respect to this compound have been filed by the same applicant as the one of the present invention Japanese PatentApplication Nos. 44558 1980 and 104420 1980 JapanesePatent Laid Open Nos. 140946 1981 and 31615 1982 . Thereafter, the inventors of the present invention have further studied on the effect of this compound in more detail and have found that the compound exhibits a carcinostatic effect enhancing effect so that it is used jointly with other knows carcinostatic drugs to enhance the carcinostatic effect thereof remarkably. The invention provides a method for enhancing the anti tumor effect, which comprises administering a therapeutically effective amount of 3,7,11 ,15 tetramethyl 2,4,6,10,14 hexadecapentaenoic acid or a salt thereof in combination with an anti tumor agent to a patient suffering from tumor. It further provides a pharmaceutical composition which comprises A 3,7,11,15 tetramethyl 2,4,6,10,14 hexadecapentaenoic acid or a salt thereof and B an anti tumor agent. Alternatively, the invention hay be defined as a pharmaceutical use of 3,7,11,15 tetramethyl 2,4,6,10,14 hexadecapentaenoic acid or a salt thereof for enhancing the anti tumor effect.In other words, the invention concerns a pharmaceutical use of 3,7,11,15 tetramethyl 2,4,6,10,14 hexadecapentaenoic acid or a salt thereof for preparing a pharmaceutical composition to enhance the anti tumor effect. The pharmaceutical agent to enhance the anti tumor effect or the carcinostatic drug to use in the invention may be any one including those which will be developed in the future Examples of the commercially available carcinostatic drugs which are used clinically and exhibit a good result include fluorouracil 5 FU , mitomycin MMC , doxorubicin hydrochloride ADM , bleomycin hydrochloride BLM , cytarabine Ara C9, pepleomycin sulfate PEP , minustine hydrochloride ACNU , carboquone CQ , cisplatin CDDP ,Thio TEPA, vincristine sulfate VCR , methotrexate MTX and cyclophosphamide CPM . The compound I of the present invention is 3,7,11,15 tetramethyl 2,4,6,10,14 hexadecapentaenoic acid represented by the formula EMI4.1 or its salt. Examples of the salt include sodium and potassium salts. The compound I of the present invention itself has a carcinostatic effect as described above. Further, when it is used together with other carcinostatic drugs, a carcinostatic effect which is remarkably enhanced by the simultaneous use of the compound I and other drugs can be obtained, though the mechanism is not clear. The compound I of the present invention is of a quite new type structurally as a carcinostatic drug or a carcinostatic synergist. The compound I exhibits a remarkably low toxicity, so that it is highly valuable clinically owing to its high safety. For reference, processes for preparing the com pound of the present invention will be described.Method A i A compound represented by the general formula II EMI5.1 is reacted with a Wittig reagent derived from a compound represented by the general formula III X C2 C021 wherein X stands for a halogen atom and R1 stands for a lower alkyl group, to prepare a compound represented by the general formula IV EMI6.1 wherein R1 is as defined above. ii The obtained compound represented by the general formula IV is hydrolyzed in the presence of a base to obtain the compound I . Examples of the TSittig reagent derived from a compound represented by the general formula III to be used in the above step i include phosphorus compounds obtained by reacting the compound represented by the general formula III with triphenylphosphine, phenyldialkoxyphosphine, trialkyl phosphine or the like. The preparation of the reagent and theWitting reaction with this reagent can be carried out by an ordinary method, such as Wadworth s method J. Am. Chem. Soc., 83, 1733 1961 , Greenwald s method J. Org. Chem., 28, 1128 1963 or Horner s method Ber. 95, 581 1962 . The hydrolysis in the above step ii can be carried out by using a base which is generally used in the hydrolysis of a carboxylate, such as sodium hydroxide or potassium hydrooxide.Method B i A compound represented by the general for mula V EMI7.1 is reacted with a Wittig reagent derived from a compound represented by the general formula VI EMI7.2 wherein X stands for a halogen atom and R1 stands for a lower alkyl group, to prepare a compound represented by the general formula IV . ii The obtained compound represented by the general formula IV is hydrolyzed in the presence of a base to obtain the compound I . These steps i and ii can be carried out in a similar manner as described in Method A.Method C i A compound represented by the general formula VII EMI8.1 wherein Y stands for a lower alkyl or aryl group, is reacted with a compound represented by the general formula VI to prepare a compound represented by the general formula VIII EMI8.2 wherein Rl and Y are as defined above. ii The obtained compound represented b the general formula VIII is desulfinated and hydrolyzed in the presence of a base to obtain the compound I . The above step i is carried out in the presence of a base. Examples of the base include n butyllithium and phenyllithium. Examples of the solvent to be used in the step i include tetrahydrofuran, dimethyl ether and 1 ,2 dimethoxyethane. The reaction is generally carried out at a room temperature or below. Examples of the substituent X in the general formulae III , it , VI , VII and VIII include halogen atoms such as chlorine, bromine or iodine, while those of the substituent R1 include lower alkyl groups such as methyl, ethyl and propyl groups. Examples of the substituent Y include lower alkyl groups such as methyl, ethyl and propyl groups and aryl groups such as phenyl and p tolyl groups. The results of pharmacological tests with the compound of the present invention will be described in the following Experimental Examples in order to illustrate the effect of the present invention in more detail.Experimental Example 1 Effect of the simultaneous use of a known carcinostatic agent and the compound I Enhancement of cytocidal effect 1 Experimental material and procedure Cell Epithelical cell from human uterocervical cancer, HeLa.S3 cell fez Cultivation The cell was cultivated using a culture fluid obtained by adding 10 parts of fetal calf serum to 90 parts of Eagles Minimum Essential Medium in an incuvator having a carbon dioxide concentration controlled to 5 at 370C. Q3 Drug The compound of the present invention was added as a solution in dimethyl sulfoxide DMSO of a final MS0 concentration of 0.1 to the culture fluid. The clinical injections as shown in Table 1 were added to the culture fluid as a known carcinostati c drug. Table 1Abbreviation Main component Trade mark 5FU fluorouracil 5 FU KyowaMMC mitomycin C Mitomycin KyowaADM doxorubicin hydro Adriacin Injection chloride bleomycin hydro Bleo chlorideAra C cytarabine Cylocide InjectionPEP pepleomycin sulfate Pepleo InjectionACNU nimustine hydro Nidran Injection chlorideCQ carboquone Exiquinon for InjectionCDDP cisplatin Randa InjectionThio.TEPA thio.tepa Tespamin InjectionVCR vincristine sulfate Oncovin CPM cyclophosphamide Endoxan for Injection o Experimental procedure 150 epithelical cells from human uterocervical cancer HeLaS3 cell were planted in each plastic dish of a diameter of 60 mm.After 4 hours, the compound of the present invention and each carcinostatic drug were simultaneously added to the dish to give a final concentration with respect to the compound of The present invention of 0, l0 6, l0 5 or 3.2X 10 5 mol M and various final concentration with respect to the drugs. After the cultivation for 7 days, the cells were fixed with methanol and subjected to Giemsa s staining, followed by calculation of the number of colonies containing at least 20 cells under a stereomicroscope. The concentration ng ml of the carcinostatic drug required to decrease the ratio of the number of colonies of a treated group to that of an untreated group control to 50 were determined and are shown as IC50 . with respect to CPM, after the aells had been cultivated in the presence of the compound of the present invention for 3 days, they were added in the presence of an S9 mix obtained by adding coenzyme or the like to an S9 fraction of the rat liver, followed by determination of IC50 in a similar manner as above. The results are shown in Table 2. Table 2EMI12.1 tb carcino SEP IC50 ng ml tb static tb drug SEP 0a SEP 10 4b a b SEP 10 5c a c SEP 32x10 5d a d tb SEP 5 SEP SEP Fu SEP 1 SEP 648 SEP 375 SEP 1.73 SEP 329 SEP 1.97 SEP 267 SEP 2.43 tb SEP 2 SEP 648 SEP 388 SEP 1.67 SEP 369 SEP 1.76 SEP 347 SEP 1.87 tb SEP Ara C SEP 1 SEP 10.9 SEP 11.9 SEP 0.92 SEP 11.4 SEP 0.96 SEP 6.25 SEP 1.74 tb SEP 2 SEP 10.9 SEP 12.0 SEP 0.91 SEP 12.4 SEP 0.88 SEP 11.6 SEP 0.94 tb SEP MMC SEP 1 SEP 1.50 SEP 1.05 SEP 1.43 SEP 0.74 SEP 2.03 SEP 0.40 SEP 3.75 tb SEP 2 SEP 1.50 SEP 1.06 SEP 1.42 SEP 0.82 SEP 1.69 SEP 0.84 SEP 1.79 tb SEP ADM SEP 1 SEP 3.79 SEP 3.10 SEP 1.22 SEP 2.45 SEP 1.56 SEP 1.80 SEP 2.02 tb SEP 2 SEP 3.79 SEP 3.51 SEP 1.08 SEP 4.15 SEP 0.91 SEP 3.14 SEP 1.21 tb SEP PEP SEP 1 SEP 8.60 SEP 75.2 SEP 1.14 SEP 4.51 SEP 1.91 SEP 14.3 SEP 6.01 tb SEP 2 SEP 2 SEP 860 SEP 739 SEP 116 SEP 531 SEP 1.62 SEP 362 SEP 2.38 tb SEP BLM SEP 1 SEP 450 SEP 450 SEP 1.05 SEP 217 SEP 2.07 SEP 61.1 SEP 7.56 tb SEP 2 SEP 450 SEP 360 SEP 1.25 SEP 490 SEP 0.92 SEP 120 SEP 3.75 tb SEP ACNU SEP 1 SEP 135 SEP 143 SEP 0.94 SEP 146 SEP 0.92 SEP 102 SEP 1.32 tb SEP 2 SEP 135 SEP 147 SEP 0.92 SEP 150 SEP 0.90 SEP 136 SEP 0.99 tb SEP CQ SEP 1 SEP 0.339 SEP 0.273 1.24 SEP 0.242 SEP 1.40 SEP 0.076 SEP 4.46 tb SEP 2 SEP 0.339 SEP 0.253 1.34 SEP 0.275 SEP 1.23 SEP 0.131 SEP 2.59 tb SEP CDDP SEP 1 SEP 45.8 SEP 34.0 SEP 1.35 SEP 37.8 SEP 1.21 SEP 37.9 SEP 1.21 tb SEP 2 SEP 45.8 SEP 37.8 SEP 1.21 SEP 42.9 SEP 1.07 SEP 59.2 SEP 0.77 tb SEP Thio TEPA SEP 1 SEP 311 SEP 274 SEP 1.14 SEP 299 SEP 1.04 SEP 274 SEP 1.14 tb SEP 2 SEP 311 SEP 291 SEP 1.07 SEP 319 SEP 0.97 SEP 244 SEP 1.27 tb SEP VCR SEP 1 SEP 5.50 SEP 7.44 SEP 0.74 SEP 6.38 SEP 0.86 SEP 2.63 SEP 2.09 tb SEP 2 SEP 5.50 SEP 7.45 SEP 0.74 SEP 7.70 SEP 0.71 SEP 5.65 SEP 0.97 tb SEP CPM SEP 1 SEP 4210 SEP 3358 SEP 1.25 SEP 1326 SEP 3.17 SEP 1225 SEP 3.44 tb SEP 2 SEP 4210 SEP 3165 SEP 1.33 SEP 1974 SEP 2.13 SEP 2304 SEP 1.83 tb The figures in Table 2 represent the IC50 values of the carcinostatic drugs. The values in parentheses represent the ratios of IC50 at a concentration of the compound of the present invention of 10 6M, 10 5M or 3.2 x 10 5M to that at a concentration of the compound of OM. That is to say, these values show the degree of the enhancement of the cytocidal effect of the carcinostatic drugs which was attained by the compound of the present invention. The figure in the upper column 1 of each carcinostatic drug represents the IC50 value based on the case where the concentrations of both the compound of the present invention and each drug are 0. The figure in the lover column 2 of each carcinostatic drug represents the IC50 value based on the case where the concentration of the compound of the present invention is l0 6, l0 5 or 3.2 x respectively, and that of the drug is 0. The cases where the degree of the enhancement of the cytocidal effect is 1.50 or above are marked by ss . It is clear from the figures of Table 2 that the compound of the present invention synergisticly enhances the cytocidal effect of a carcinostatic drug.The effect is particularly remarkable in the case of 5FU, MMC, PEP, ELM, CQ or CPM. Experimental Example 2 Toxicological test The compound of the present invention, 3,7,ll,15 tetramethyl 2,4,6,l0,14 hexadecapentaenoic acid, was administered orally to each group consisting of six female ICR mice for 14 days at a dosage of 40, 200 or 400 mg kg day, respectively, to observe changes in the weight, the mortality or the like. No mice died and an adverse reaction such as decrease in weight or cyanosis was not observed. It should be understood from the above ExperimentalExamples 1 and 2 that the compound of the present invention is remarkably effective in enhancing a carcinostatic effect and that it is used together with a carcinostatic drug to remarkably enhance the carcinostatic effect. Additionally, it is clear from the toxicological test that the compound of the present invention is highly safe, so that the present invention is highly valuable in this sense, because a carcinostatic drug must be administered for a long time from the nature of the disease. When the compound of the present invention is used together with other carcinostatic drug as a carcinostatic synergist, it may be administered in the form of a previously prepared compound preparation containing the compound and the carcinostatic drug, for example, in the form of injection, powder, granular, tablet or capsule. Alternatively, the compound and the carcinostatic drug may be administered simultaneously and separately to patients. The carcinostatic drug to be used together with the compound of the present invention may be any one in a very wide range including existing ones and ones which will be developed in the suture Representative examples of the drugs which exhibit good results include those based on vinca alkaloid such as vincristine, vinblastine, vindesine and Of16 adriamycin compounds such as doxorubicin hydrochloride adriamycin and daunomycin 5 FU compounds, mitomycin C, bleomycin hydrochloride, cytarabine, pepl eomycin sulfate, nimustine hydrochloride, carboquone, cisplatin and Thio tepa. When the compound of the present invention is used as a carcinostatic synergist, the amount to be administered is not particularly limited and is varied depending upon the kind of a carcinostatic drug, the kind of cancer, the condition of a patient or the like.Generally, the compound is administered orally or nonorally at a dosage of about 10 to 2000 mg, preferably 5 to 500 mg per adult a day. The compound can be administered in the form of injection, powder, fine granule, granule, tablet, capsule or the like. The preparation is carried out using an ordinary carrier in a conventional manner. More particularly, when a solid preparation for oral administration is manufactured, a principal agent is mixed with a vehicle, if necessary, together with binder, disintegrating agent, lubricant, coloring agent or corrigent, and treated according to an ordinary method to be formed into tablet, coated tablet, granule, capsule or the like. Examples of the vehicle to be used include lactose, corn starch, white sugar, dextrose, sorbitol, crystal line cellulose and silicon dioxide. Examples of the binder include polyvinyl alcohol, polyvinyl ether, ethylcellulose, methylcellulose, gum arabic, tragacanth, gelatin, shellac, hydroxypropylcellulose, hydroxypro pylstarch, polyvinylpyrrolidone, white sugar and sor bitol. Examples of the disintegrating agent include starch, agar agar, gelatin powder, crystalline cellu lose, calcium carbonate, sodium bicarbonate, calcium citrate, dextrin and pectin. Examples of the lubri cant include magnesium stearate, talc, polyethylene glycol, silica and hardened vegetable oil. The coloring agent is any one which is permitted to be added to medicines. Examples of the corrigent include cocoa powder, menthol, aromatic powder, peppermint oil, borneol and cinnamon powder.These tablets and granules may be coated with sugar, gelatin or the like. When a liquid preparation for oral administration is manufactured, a principal agent is, if necessary, mixed with corrigent, buffer, stabilizer or the like, and formed into a syrup or the like according to an ordinary method. When an injection is manufactured, a principal agent is, if necessary, mixed with pH regulator, buffer, suspending agent, dissolution auxiliary, stabilizer, isotonizing agent, preservative or the like, and formed into subcutaneous, intramuscular or intravascular injection according to an ordinary method. Examples of the suspending agent include methylcellulose, polysolvate 80, hydroxyethylcellulose, gum arabic, tragacanth powder, sodium carboxymethylcellulose and polyoxyethylene sorbitan monolaurate.Examples of the dissolution auxiliary include poly oxyethylene ha iened castor oil, polysolvate 80, nicotinamide, polyoxyethylene sorbitan monolaurate, macrogol. Examples of the stabilizer include sodium sulfite, sodium metasulfite and ethers. Examples of the preservative include methyl p hydroxybenzoate, ethyl p hydroxybenzoate, sorbic acid, phenol, cresol and chlorocresol. Preparative Examples will be described for reference.Preparative Example 1 Preparation of 3,7,ll,l5 tetramethyl 2,4,6,lO,14 hexadecapentaenoic acid 28.6 g of triethylphosphonoacetate was added to a suspension consisting of 5.0 g of 55 sodium hydride oily and 60 mss of n hexane. The resulting solution was heated under reflux and 20 g of 6,10,14 trimethyl pentadeca 3,5,9,13 tetraen 2 one was added dropwise to the solution under stirring. After 30 minutes, the reaction mixture was poured onto 200 mS of icewater and extracted with 500 me of hexane. The hexane layer was twice washed with 100 mS of a mixture of methanol and water 2 1 and concentrated. The concentrate was purified by silica gel column chroma tography to obtain 18 g of ethyl 3,7,11,15 tetramethyl 2,4,6,10 ,l4 hexadecapentaenoate 3.9 g of potassium hydroxide was dissolved in 30 mB of isopropyl alcohol. 10 g of the above hexadecapentaenoate ester was added to the resulting solution. The mixture was stirred at 50 0C for one hour. The reaction mixture was poured onto ice water, made acid with hydrochloric acid and extracted with 100 mS of ethyl ether. The ether layer was washed with water, dried over magnesium sulfate and concentrated to obtain 9.0 g of an oil. The oil was dissolved in 50 mS of n hexane and crystallized at 200C to obtain 4.0 g of 3,7,11,15 tetramethyl 2,4,6,10,14 hexadecapen taenoic acid as a pale yellow needle crystal. melting point 78.4 C mass spectrum m e 302 M infrared absorption spectrum cm , KBr tablet 3450, 2900, 1680, 1595 NMR spectrum , CDCl3 1.61 6H,s , 1.68 3H,s , 1.86 3H,s , 1.92 to 2.24 8H,b , 2.35 3H,s , 5.10 2H,b , 5.76 lH, bs , 5.98 lH,d,J llHz , 6.20 1H,d,J 15Hz , 6.90 1H,dd,J 11Hz,15Hz , 11.63 lH,b ultraviolet absorption spectrum maxmethanol 304 nm.